Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Stifel Reiterates Buy on Momenta Pharma (MNTA) Following Positive Phase 3 Data November 29, 2016 10:28 AM Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) BiosimilarNovember 29, 2016 8:00 AM